Interestingly, although these transcription regulations might explain the reduction of CD95 observed in many tumors, the estrogen receptor-negative TNBC cells maintain a higher level of CD95 as compared with other breast tumors (Blok et al., 2017). Here, ESR1 is linked to breast neoplasm.